Bavarian Nordic — Februar 2023
-
Verdenssundhedsorganisationen WHO har tirsdag indkaldt til hastemøde, efter der er sket et udbrud af Marburgvirus i Ækvatorialguinea. Bavarian har arbejdet med dette - kender ikkevresultatet… viser igen igen at Bavarian har meget interessant pipeline
-
-
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
The search for a universal filovirus vaccine that provides protection against multiple filovirus species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic vaccine should be able to provide protection to all known filovirus species and as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity and protection elicited by multivalent vaccines expressing glycoproteins (GP) from Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV) and Marburg virus (MARV). Immune responses against filovirus GP have been associated with protection from disease. The GP antigens were expressed by adenovirus serotypes 26 and 35 (Ad26 and Ad35) and modified Vaccinia virus Ankara (MVA) vectors, all selected for their strong immunogenicity and good safety profile. Using fully lethal NHP intramuscular challenge models, we assessed different vaccination regimens for immunogenicity and protection from filovirus disease. Heterologous multivalent Ad26-Ad35 prime-boost vaccination regimens could give full protection against MARV (range 75%-100% protection) and EBOV (range 50% to 100%) challenge, and partial protection (75%) against SUDV challenge. Heterologous multivalent Ad26-MVA prime-boost immunization gave full protection against EBOV challenge in a small cohort study. The use of such multivalent vaccines did not show overt immune interference in comparison with monovalent vaccines. Multivalent vaccines induced GP-specific antibody responses and cellular IFNγ responses to each GP expressed by the vaccine, and cross-reactivity to TAFV GP was detected in a trivalent vaccine expressing GP from EBOV, SUDV and MARV. In the EBOV challenge studies, higher humoral EBOV GP-specific immune responses (p = 0.0004) were associated with survival from EBOV challenge and less so for cellular immune responses (p = 0.0320). These results demonstrate that it is feasible to generate a multivalent filovirus vaccine that can protect against lethal infection by multiple members of the filovirus family.
(journals.plos.org)
-
Godmorgen
-
Godmorgen. Ca. 6 mia. i forventet 2023 omsætning. Ikke langt fra den forventning, jeg tidligere har udtrykt herinde og noget fra de op til 8 mia. nogen andre, har udtrykt. I gang med nærlæsning. God dag til jer alle også Mikko og Sus
-
Bavarian spår stort milliardoverskud på driften https://www.proinvestor.com/boards/110463
-
@Bibob. Mon ikke forventningen til cov2 efterhånden er tæt på en pris af nul kr. målt på dagsværdien?
-
Jeg skal indskærpe til alle, at de personligt rettede kommentarer nu stoppes i denne chat. Såfremt de forsættes vil de pågældende ekskluderes. Jeg og Stroka orker ikke at bruge mere tid at slette indlæg.
-
Hvis den er rettet til mig Helge, så er det modtaget og jeg beklager, at jeg har skudt igen.
-
Den er rettet mod alle deltagere i den slags.
-
Ok. Jeg har i hvert fald beklaget min del....
-
I lige måde LP90
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind